These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 29152725)

  • 1. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.
    Mauzo SH; Tetzlaff MT; Nelson K; Amaria R; Patel S; Aung PP; Nagarajan P; Torres-Cabala CA; Diab A; Prieto VG; Curry JL
    Int J Dermatol; 2019 Sep; 58(9):1045-1052. PubMed ID: 29152725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma.
    Nakamura Y; Fujino T; Kagamu H; Matsuya T; Teramoto Y; Asami Y; Yamamoto A
    JAMA Dermatol; 2017 Aug; 153(8):832-834. PubMed ID: 28492864
    [No Abstract]   [Full Text] [Related]  

  • 3. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
    Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
    Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study.
    Zhao CY; Hwang SJE; Wakade D; Carlos G; Anforth R; Fernández-Peñas P
    Australas J Dermatol; 2017 Nov; 58(4):292-298. PubMed ID: 28707403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanocytic nevi and melanoma: unraveling a complex relationship.
    Damsky WE; Bosenberg M
    Oncogene; 2017 Oct; 36(42):5771-5792. PubMed ID: 28604751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib.
    McClenahan P; Lin LL; Tan JM; Flewell-Smith R; Schaider H; Jagirdar K; Atkinson V; Lambie D; Prow TW; Sturm RA; Soyer HP
    JAMA Dermatol; 2014 Oct; 150(10):1079-82. PubMed ID: 24695877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
    Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
    J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agminated melanocytic nevus status post dabrafenib therapy for metastatic melanoma.
    Agulló A; Hinds B; Santesteban R; Mitxelena JM; Yanguas I
    Dermatol Online J; 2016 Jul; 22(7):. PubMed ID: 27617734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive melanoma in an infant with congenital melanocytic nevus syndrome and multiple, NRAS and BRAF mutation-negative nodules.
    de la Rosa Carrillo D; Vindenes H; Kinsler VA; Rønnestad A; Ringstad G; Müller LO; Tafjord S; Tønseth KA; Kvamme B; Clausen OPF
    Pediatr Dermatol; 2018 Sep; 35(5):e281-e285. PubMed ID: 29999207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.
    Mochel MC; Hammond MR; Frederick DT; Alora-Palli MB; Piris A; Flaherty KT; Hoang MP
    J Am Acad Dermatol; 2015 Sep; 73(3):491-9.e2. PubMed ID: 26190239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous regression of multiple melanocytic nevi after melanoma: report of 3 cases.
    Martín JM; Pinazo I; Monteagudo C; Markovic J; Allende A; Jordá E
    Am J Dermatopathol; 2014 Nov; 36(11):e183-8. PubMed ID: 25343215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer.
    Meneguzzo A; Lazzarotto A; Alaibac M
    In Vivo; 2020; 34(1):441-445. PubMed ID: 31882511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.
    Chen FW; Tseng D; Reddy S; Daud AI; Swetter SM
    JAMA Dermatol; 2014 Nov; 150(11):1209-12. PubMed ID: 25142409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
    Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
    Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.